Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke

NCT ID: NCT02184936

Last Updated: 2017-10-30

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2016-09-30

Brief Summary

Treatment of acute ischemic stroke (AIS) is aimed at salvaging viable but ischemic brain by opening the occluded artery and restoring anterograde perfusion as quickly as possible. Time saved while making critical decisions correctly is vital in AIS management. Conventional angiography is invasive, resource intensive and not feasible as a fast diagnostic tool. Perfusion CT and MRI are both susceptible to patient motion, need trained personnel to process and take at least 10-30 min to acquire and interpret. The investigators have developed a new imaging tool, multi-phase CT Angiography (CTA), which generates multiple time resolved images of backfilling arteries beyond a blocked artery filled by collaterals.

Investigators seek to determine: i) if patients with AIS will have a differential clinical response to early recanalization based on collateral status assessed on multi-phase CTA, ii) if the extent to which collateral assessment on multi-phase CTA resembles perfusion CT in predicting which patients will have good clinical outcome with early recanalization, iii) Identify determinants of variability in native collateral status in patients with acute ischemic stroke.

Investigators hypothesize that patients with good and intermediate collaterals on multi-phase CTA achieve good clinical outcome with early recanalization (within 4 hours of baseline imaging); patients with poor collaterals do not do well even with early recanalization.

Prove-IT is a prospective multi-center hospital-based cohort study of 500 consecutive patients with acute ischemic stroke presenting within 12 hours of stroke symptom onset with evidence of intracranial occlusion on routine CTA over 3 years. Calgary and seven other comprehensive stroke centers will recruit patients into this study. Primary outcome is defined as a National Institute of Health Stroke Scale (NIHSS) score of 0 to 2 at 24 hours or an 8-point drop in NIHSS score from baseline to 24 hours. Secondary outcomes are a) 90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke mRS; b) percent neurologic improvement comparing NIHSS at baseline to 24 hours; c) 90-day NIHSS score 0-2; d) infarct volume on 24 hour imaging and e) parenchymal intracerebral hemorrhage type 1 and 2 (ECASS II criteria) at 24 hrs.

Prove-IT looks to establish the ideal imaging selection tool for intra-arterial (IA) and thrombolysis decisions in the setting of AIS which is widely available, and can quickly and reliably detect salvageable brain.

Conditions

Ischemic Stroke

Keywords

CT Angiography, CT Perfusion, Ischemic Stroke, Collaterals

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

acute ischemic stroke

standard of care

Intervention Type: OTHER

Interventions

standard of care

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Patient presenting to the emergency department with symptoms consistent with ischemic stroke.

2. Age > 18 yrs.

3. Baseline imaging including multi-phase CTA done within 12 hours of stroke symptom onset and initiated before recanalization therapy.

4. Evidence of a visible and symptomatic intracranial occlusion on baseline CT-angiography (intracranial ICA, M1 MCA segment +/- intracranial ICA, proximal M2 MCA).

5. Treatment with IV tPA and/or IA therapy.

Exclusion Criteria

1. Intracranial hemorrhage (ICH) identified on baseline CT.

2. Previous moderate to large stroke in the ipsilesional hemisphere.

3. Modified Rankin Scale > 2 at baseline.

4. Unable to have CT-angio performed due to recent estimated creatinine clearance eCCr<60 ml/min, contrast allergy or other reasons.

5. Participation in another study that results in the patient receiving an investigational drug or therapy.

6. Any terminal illness (patient not expected to survive > 1 year).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Carol Kenney

OTHER

Sponsor Role: lead

Responsible Party

Carol Kenney

Study co-ordinator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Bijoy Menon, MD

Role: PRINCIPAL_INVESTIGATOR

University of Calgary, Calgary Stroke Program

Locations

Foothills Medical Centre

Calgary, Alberta, Canada

Arcispedale Sant'Anna · Department of Neurology

Ferrara, , Italy

Countries

Canada; Italy

Other Identifiers

24416

Identifier Type: -

Identifier Source: org_study_id